PARIS, France, 08:00 am, August 10, 2020 (CET) – Pharnext SA (FR0011191287 - ALPHA), an advanced clinical-stage biopharmaceutical company pioneering new approaches to develop innovative drug combinations based on big genomics data and artificial intelligence, today announced the appointment of Adrian Hepner, M.D., Ph.D., as Chief Medical Officer of Pharnext, effective as of August 10, 2020.
“We are delighted to welcome Adrian to the executive team at Pharnext,” said Dr. David Horn Solomon, Chief Executive Officer. “With his strong track record of advancing candidates through all stages of clinical development and through regulatory approval, as well as significant experience in conducting global clinical research programs, leading drug development and medical affairs teams, developing and implementing regulatory strategies and filing marketing applications in the U.S. and Europe, we are confident Adrian will marshal his experience to progress our late-stage candidate PXT3003 for the treatment of CMT1A, a rare neurological disease, through the clinic and on to the market.
In addition, Adrian’s specialized clinical and research background in neurological diseases will enable us to further expand and develop our clinical development pipeline for rare neurological indications and other areas of high unmet need.”
Dr. Hepner joins Pharnext with over 30 years of clinical practice and industry experience in biomedical research, clinical drug development and medical affairs. Prior to joining Pharnext, he served as Executive Vice President and Chief Medical Officer at Eagle Pharmaceuticals. Before that, Dr. Hepner’s roles included Vice President of Clinical Research at Avanir Pharmaceuticals, Vice President of Clinical Research and Medical Affairs at BioDelivery Sciences International (BDSI) and Senior Medical Director at UCB BioSciences, Inc. He started his career as the Director of the Inpatient Unit and Clinical Research at Clinica Emanu-El in Buenos Aires, Argentina, where he focused on the treatment of major neuropsychiatric and neurobehavioral disorders, as well as clinical drug research. Dr. Hepner received an M.D. and Ph.D. in Psychiatry and Neurology from the University of Buenos Aires. He also completed a post-doctoral fellowship in Neuro-Psychopharmacology at the University of Ottawa and held visiting research physician positions in the Department of Psychiatry at Harvard Medical School and the Department of Neurology at the National Institute of Mental Health.
“I am very pleased to join Pharnext at such an exciting time of growth, especially as our late-stage candidate, PXT3003, is making important progress to treat CMT1A,” said Dr. Hepner. “Throughout my career, I’ve been passionate about developing and advancing innovative therapies for neurological disorders of high unmet need and look forward to continuing to do so at Pharnext by developing and expanding its pipeline from the PLEOTHERAPY™ platform.”
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 completed an international Phase III trial with positive topline results for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated encouraging Phase II results in Alzheimer’s disease. Pharnext has developed a new drug discovery paradigm based on big genomics data and artificial intelligence: PLEOTHERAPY™. Pharnext identifies and develops synergic combinations of drugs called PLEODRUG™. The Company was founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics, and is supported by a world-class scientific team. More information at www.pharnext.com.
Pharnext is listed on the Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287).
This press release contains certain forward-looking statements concerning Pharnext and its business. Such forward-looking statements are based on assumptions that Pharnext considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in Pharnext’s document de base filed with the AMF on June 2, 2016 under number I.016-0050 as well as in its annual periodic management reports and press releases (copies of which are available on www.pharnext.com) and to the development of economic conditions, financial markets and the markets in which Pharnext operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Pharnext or not currently considered material by Pharnext. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Pharnext to be materially different from such forward-looking statements. Pharnext disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Pharnext shares in any country.